Comparing Two Imaging Scans for Neuroendocrine Tumors
Part of Cancer clinical trials.
This trial compares two types of PET scans to see which one better detects neuroendocrine tumors (rare cancers that grow slowly in the body). You'll receive both scans to help doctors understand which imaging method works best.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have a known or suspected neuroendocrine tumor that your doctor wants to investigate
- You are able and willing to have two PET/CT scans (specialized imaging tests)
- You weigh less than 450 pounds and can fit through the scanner opening
- You are not pregnant or breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses a PET/CT scan with a small amount of radioactive tracer to see how neuroendocrine tumors are behaving in adults. It may help doctors better detect and evaluate these tumors, especially when symptoms suggest a carcinoid-type hormone problem.
This study compares a new imaging agent (Al18F-NOTA-LM3) with two existing ones (68Ga-DOTATATE and 68Ga-NODAGA-LM3) during PET/CT scans to see if it's better at finding well-differentiated neuroendocrine tumors. Participating may help improve how these tumors are detected.
This trial looks at how useful a specific scan (68Ga-DOTA-TATE PET/CT) is for tumors that have certain “targets” (somatostatin receptors). It may help doctors better identify and guide care for neuroendocrine tumors.
This trial tests a new type of PET scan using a radioactive tracer called 61Cu-NODAGA-LM3 to detect neuroendocrine tumors (NETs). The goal is to see if it works as well as or better than the standard scan. If you have a NET and need a scan for staging or treatment planning, you might be able to join.
This early-phase study tests whether a special scan using 68Ga-HA-DOTATATE can help identify or diagnose tumors that have “somatostatin receptors.” It also checks how safe this scanning approach is and whether it provides useful information for people who may have these tumor types.
This trial tests a special PET scan to better evaluate gastroenteropancreatic neuroendocrine tumors (GEP-NETs). It may help your doctor see where the tumors are in your body.
Hear when a new Neuroendocrine Tumors, NET trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.